A single center observational study on emergency department clinician non-adherence to clinical practice guidelines for treatment of uncomplicated urinary tract infections. by Zatorski, Catherine et al.
UC Davis
UC Davis Previously Published Works
Title
A single center observational study on emergency department clinician non-adherence to 
clinical practice guidelines for treatment of uncomplicated urinary tract infections.
Permalink
https://escholarship.org/uc/item/1qk7v1q2
Journal
BMC infectious diseases, 16(1)
ISSN
1471-2334
Authors
Zatorski, Catherine
Zocchi, Mark
Cosgrove, Sara E
et al.
Publication Date
2016-11-04
DOI
10.1186/s12879-016-1972-6
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
RESEARCH ARTICLE Open Access
A single center observational study on
emergency department clinician non-
adherence to clinical practice guidelines for
treatment of uncomplicated urinary tract
infections
Catherine Zatorski1, Mark Zocchi2, Sara E. Cosgrove3, Cynthia Rand4, Gillian Brooks1 and Larissa May5*
Abstract
Background: The Emergency Department (ED) is a frequent site of antibiotic use; poor adherence with evidence-
based guidelines and broad-spectrum antibiotic overuse is common. Our objective was to determine rates and
predictors of inappropriate antimicrobial use in patients with uncomplicated urinary tract infections (UTI) compared
to the 2010 International Clinical Practice Guidelines (ICPG).
Methods: A single center, prospective, observational study of patients with uncomplicated UTI presenting to an
urban ED between September 2012 and February 2014 that examined ED physician adherence to ICPG when
treating uncomplicated UTIs. Clinician-directed antibiotic treatment was compared to the ICPG using a standardized
case definition for non-adherence. Binomial confidence intervals and student’s t-tests were performed to evaluate
differences in demographic characteristics and management between patients with pyelonephritis versus cystitis.
Regression models were used to analyze the significance of various predictors to non-adherent treatment.
Results: 103 cases met the inclusion and exclusion criteria, with 63.1 % receiving non-adherent treatment, most
commonly use of a fluoroquinolone (FQ) in cases with cystitis (97.6 %). In cases with pyelonephritis, inappropriate
antibiotic choice (39.1 %) and no initial IV antibiotic for pyelonephritis (39.1 %) where recommended were the most
common characterizations of non-adherence. Overall, cases of cystitis were no more/less likely to receive non-
adherent treatment than cases of pyelonephritis (OR 0.9, 95 % confidence interval 0.4–2.2, P = 0.90). In multivariable
analysis, patients more likely to receive non-adherent treatment included those without a recent history of a
UTI (OR 3.8, 95 % CI 1.3–11.4, P = 0.02) and cystitis cases with back or abdominal pain only (OR 11.4, 95 % CI
2.1–63.0, P = 0.01).
Conclusions: Patients with cystitis with back or abdominal pain only were most likely to receive non-
adherent treatment, potentially suggesting diagnostic inaccuracy. Physician education on evidence-based
guidelines regarding the treatment of uncomplicated UTI will decrease broad-spectrum use and drug
resistance in uropathogens.
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Background
The burden of increasingly resistant bacterial infections
strains our healthcare system and is a major global pub-
lic health challenge [1]. Antimicrobial stewardship pro-
grams aim to improve antimicrobial use and reduce
emergence of resistance through a variety of mecha-
nisms, but few systematic efforts to date have been made
to perform antimicrobial stewardship in the emergency
department (ED) setting [2]. The ED is a frequent site of
antibiotic use and thus, provides a unique opportunity
for antimicrobial stewardship. Up to half of all anti-
microbial prescriptions are inappropriate [3], with poor
adherence with evidence based guidelines (EBG) for in-
fectious diseases [4, 5] and overuse of broad spectrum
antibiotics [6, 7]; however, this has not been quantified
in an ED setting.
Urinary tract infections (UTI) are one of the most
common complaints diagnosed in the ED and
accounted for approximately 2.4 million visits in 2010
[8]. Uncomplicated UTIs encompass acute, uncompli-
cated cystitis and pyelonephritis in outpatient, non-
pregnant women [9]. Given that nearly half of all ED
visits are by patients with non-life-threatening prob-
lems [10], emergency physicians must be adept at
treating these illnesses. However, the natural limita-
tions of the ED setting, such as inadequate microbio-
logical testing and follow up, necessitates the use of
treatment recommendations based on clinical findings
in EBGs to minimize antimicrobial resistance and ad-
verse events associated with broad spectrum antibiotic
use.
The 2010 International Clinical Practice Guidelines
(ICPG) established by the Infectious Diseases Society
of America (IDSA) and the European Society for
Microbiology and Infectious Diseases (ESCMID) up-
dated the previous 1999 recommendations to account
for changes in resistance, the increased adverse effects
of antimicrobial therapy, and new antimicrobial agents
available. It remains the most current guideline re-
garding treatment of uncomplicated UTI endorsed by
the IDSA. In the absence of fever, flank pain, or other
symptoms of pyelonephritis, fluoroquinolones are no
longer first-line due to the increase in resistance and
the propensity for side effects, a major departure from
the 1999 guidelines [11]. Nitrofurantoin, fosfomycin, and
trimethoprim-sulfamethoxazole (TMP-SMX) where com-
munity resistance rates are <20 % are recommended as
first-line therapy for cystitis. Ciprofloxacin is preferred for
pyelonephritis [9].
Our study objective was to determine proportions and
predictors of inappropriate antimicrobial use as defined
by 2010 ICPG established by the IDSA and the ESMID
in emergency department patients presenting with a
urinary tract infection.
Methods
This was a prospective, observational study that was
reviewed and approved by the Institutional Review
Board at The George Washington University. We en-
rolled non-pregnant women, between the ages of 18 and
49 years, in an urban, academic ED in a tertiary care
hospital in Washington, DC, USA with approximately
75,000 patient visits per year between September 2012
and February 2014. All participants provided informed
consent in accordance with standards set forth by HHS
regulations 45 CFR 46.11a and FDA regulations 21 CFR
50.25. IDSA guidelines are endorsed by hospital infec-
tion control for antibiotic choice and a hospital-wide
antibiogram is not readily available to ED clinicians and
is not specific to uropathogens. Inclusion criteria in-
cluded complaints of symptoms consistent with a UTI,
including dysuria, increased frequency of urination, and
hesitancy to urinate, those who had a urine dipstick,
urinalysis with microscopy, and/or urine culture or-
dered. Results of the urine culture were not available to
the clinical staff during the course of patient care and
were used exclusively for research purposes or clinical
follow up. Women were excluded if they were previously
treated for a UTI within the past month due to the pos-
sibly of treatment failure from the previous infection
[12–14], were currently on antibiotics, had severe co-
morbidities (diabetes mellitus, end stage renal disease, or
immunocompromised) or had a recent urologic proced-
ure or indwelling catheter. Enrollment occurred Monday
to Friday, 8 am–7 pm, and Saturday to Sunday, 9 am–
5 pm, due to the presence of department research assis-
tants. Consecutive enrollment was attempted during this
time. Clinical decision-making was at the discretion of
the individual healthcare provider. At our site care for
uncomplicated UTIs is primarily performed in the ED
ambulatory care track by emergency medicine (EM)
trained physicians and physician assistants (PA); how-
ever, EM residents (Post Graduate Years 1 through 4)
and non-EM residents who rotate in the ED and also
provide care. All clinical decisions made by physician as-
sistants and EM residents are reviewed and approved by
a board-certified EM physician prior to patient dis-
charge. Pharmacists do not approve antibiotic prescrip-
tions prior to administration or discharge.
Potential participants were screened for eligibility
using the ED’s electronic medical record (EMR) and, if
eligible, were approached for participation. Those who
gave informed consent had demographic, behavioral,
clinical, and treatment information collected through
structured interview with the patient and clinician.
Treatment information was collected by interview right
after the clinical encounter. Urine cultures were pro-
spectively collected to ascertain pathogen type and sus-
ceptibility information. Urine dipstick, urinalysis with
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microscopy, and culture results were collected via chart
abstraction of the EMR.
Clinician-directed antibiotic treatment was compared
to the guideline recommendations, and took into ac-
count allergy. No attempt was made to familiarize treat-
ing providers with guideline recommendations. We
developed a standard case definition for non-adherence.
Antibiotic use was not considered consistent with guide-
lines if the patient received a FQ in the absence of fever
and/or flank pain and did not have a documented allergy
to nitrofurantoin or to sulfonamides, received less than
the recommended dose or duration according to the
IDSA guidelines, or had a regimen longer than 2 days
over the recommended duration. Clinical and demo-
graphic characteristics were collected via structured data
form and chart abstraction was performed for verifica-
tion. Given our institution does not have an outpatient
or ED specific antibiogram and the hospital wide anti-
biogram is not widely distributed in this setting, we as-
sumed the use of TMP-SMX as guideline adherent since
providers may assume lower resistance for patients with
uncomplicated infection. Final International Classification
of Disease 9 (ICD9) diagnosis was reviewed by an inde-
pendent emergency physician to ensure that diagnosis
correlated with signs and symptoms recorded in the pa-
tient’s electronic medical record. We categorized cases as
pyelonephritis or cystitis through direct interview of the
clinician as well as review of the electronic medical record
of the patient’s symptoms and the treating provider’s clin-
ical impression as documented on the chart. Our case def-
inition of pyelonephritis included the presence of fever or
flank pain as per patient report. In instances where our
case definitions did not match the clinical diagnosis we
evaluated adherence per the clinician diagnosis (n = 11).
We conduct a sensitivity analysis with these cases ex-
cluded and compare our results.
Results were summarized using proportions (%) for
categorical data with binomial confidence intervals. Cat-
egorical variables were compared using either Pearson’s
Chi-squared or Fisher’s exact test, where appropriate. To
determine the predictors of non-adherence, univariate
followed by multivariable logistic regression analysis
were performed. Predictors included: patients’ age, race
(black, white, or other), provider type (resident vs. at-
tending or PA), current sexual activity (yes/no), prior
history of UTI outside the 1-month exclusion, diagnosis
of pyelonephritis, decreased urine output, frequent
urination, dysuria, abdominal pain, back pain, nausea/
vomiting, vaginal discharge, days since onset of symp-
toms and urine analysis result. All variable was consid-
ered potentially significant and further analyzed in a
stepwise multivariate logistic regression model using the
backward selection method for determining significant
independent factors at P < 0.2. While these are a large
number of variables to include, prior research demon-
strates a variety of factors leading to overprescribing of
broad spectrum antibiotics in cases of diagnostic uncer-
tainty or clinical presentation, thus we felt it important
to include demographic, clinical and test factors in our
model [15, 16]. To reduce the number of variables in-
cluded in the regression analyses, we collapsed urinary
symptoms together (dysuria, frequent urination, and de-
creased urination) and non-urinary clinical symptoms
together (back pain, abdominal pain, nausea/vomiting,
and vaginal discharge). Odds ratios with 95 % confidence
intervals were calculated. Predictors with a p-value of
less than 0.05 were considered statistically significant.
The final model was tested for fit using a Hosmer-
Lemeshow X2 (1.84, P = 0.97). Stata, v.13 (College Station,
TX, USA) was used for all analyses.
Results
A total of 103 of 445 patients met the inclusion and ex-
clusion criteria. Of these, a total of 65 (63.1 %) received
treatment that did not adhere to the ICPG guidelines.
Sixty-seven patients were identified as cystitis, of which
42 received treatment non-adherent to the guidelines
(62.7 %). The most common characterization of non-
adherence in cystitis was inappropriate use of a FQ,
which occurred in 97.6 % (41/42) of the non-adherent
cases. Thirty-six patients were identified as Pyeloneph-
ritis, of which 23 received treatment non-adherent to
the guidelines (63.9 %). The most common description
of non-adherence in pyelonephritis was inappropriate
antibiotic choice and no initial IV antibiotic, which both
occurred in 39.1 % (9/23) of the non-adherent cases. We
found that 22.2 % of E. coli isolates from patients with
uncomplicated UTI in our study were resistant to TMP-
SMX, and 8.0 % to FQ (data not shown).
Baseline characteristics of patients with pyelonephritis
compared to cystitis are presented in Table 1. Patients
with pyelonephritis had higher prevalence of abdominal
pain (75.0 % vs. 43.3 %, P < 0.01), back pain (69.4 % vs.
28.4 %, P < 0.01), nausea/vomiting (36.1 % vs 11.9 %,
P < 0.01) than patients with cystitis. They were also
more likely to have had symptoms for more than
4 days (58.3 vs 28.8 %, P < 0.01).
Characteristics of patient management and diagnostic
results of patients with pyelonephritis versus cystitis are
shown in Table 2. Residents were more likely to treat pa-
tients with pyelonephritis compared to cystitis (52.8 vs
25.4 %; P < 0.01). Non-adherence to guidelines was
similar for patients with pyelonephritis and cystitis
(63.9 % vs. 62.7 %; P = 0.90).
In the univariate analysis, patients with cystitis with
back or abdominal pain had increased odds of receiving
non-adherent treatment compared to patients with
cystitis but no other non-urinary symptoms (OR 8.8,
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95 % CI 1.7–45.9) as were patients with no recent his-
tory of an UTI (OR 2.4, 95 % CI 1.0–5.7) (Table 3).
Patients with nausea or vomiting symptoms (any
diagnosis) had reduced odds of receive guideline non-
adherent treatment compared to patients without
those symptoms (OR 0.3; 95 % CI 0.1–0.9). The mul-
tivariable model included, no recent history of UTI,
type of UTI with symptoms, and nausea/vomiting.
(Table 4). Physicians were more likely to be guideline
non-adherent for patients with no recent history of
UTI (OR 3.8; 95 % CI 1.3–11.4) –0.9), had cystitis
with back or abdominal symptoms only (OR 11.4;
95 % CI 2.1–63.0), or had cystitis with vaginal dis-
charge (OR 12.1; 95%CI 1.1–137.5). The wide confi-
dence intervals of the clinical subgroups with small
numbers of patients should be interpreted with cau-
tion. In a sensitivity analysis excluding patients where
the clinician diagnosis did not match our case defin-
ition (n = 11) nausea/vomiting was dropped from the
model and cystitis with vaginal discharge was no lon-
ger a significant predictor of non-adherence (p = 0.07).
Cystitis with back or abdominal pain only and no re-
cent history of UTI remained significant.
Discussion
We found a high degree of non-adherence to current
guidelines for the treatment of UTI; namely, the overuse
of FQ in patients with uncomplicated cystitis and in-
appropriate antibiotic choice and no initial IV antibiotic
for pyelonephritis. Interestingly, providers were more
likely to be non-adherent with guidelines for cystitis
cases where patients only had back or abdominal pain
and for cases without a recent history of UTI. Providers
were also more likely to be guideline non-adherent for
patients with vaginal discharge, however this result was
not statistically significant in our sensitivity analysis. The
results potentially suggest diagnostic inaccuracy as well
as overuse of broad spectrum antibiotics for patients
with vaginal discharge and prior UTI. Only 19.4 % of
our patients with uncomplicated cystitis received the
first line agent of nitrofurantoin, despite the low rate of
resistance compared to other antimicrobial agents.
Table 1 Patient demographic and clinical characteristics of 103 adults treated for uncomplicated UTI
Characteristics Overall (n = 103) Pyelonephritis (n = 36) Cystitis (n = 67) P-value
% (95 % CI) % (95 % CI) % 95 % CI)
Race/ethnicity
Black, non-Hispanic 51.5 (41.4–61.4) 55.6 (38.1–72.1) 49.3 (36.8–61.8) 0.74
White, non-Hispanic 31.1 (22.3–40.9) 30.6 (16.3–48.1) 31.3 (20.6–43.8)
Hispanic or other race 17.5 (10.7–26.2) 13.9 (4.7–29.5) 19.4 (10.8–30.9)
Age, y
18–29 64.1 (54.0–73.3) 47.2 (30.4–64.5) 73.1 (60.9–83.2) <0.01
30–39 25.2 (17.2–34.8) 44.4 (27.9–61.9) 14.9 (7.4–25.7)
40+ 10.7 (5.5–18.3) 8.3 (1.8–22.5) 11.9 (5.3–22.2)
Clinical history
Sexually active 83.5 (74.9–90.1) 77.8 (60.8–89.9) 86.6 (76.0–93.7) 0.25
No recent history of UTI 38.8 (29.4–48.9) 36.1 (20.8–53.8) 40.3 (28.5–53.0) 0.68
Clinical symptoms
Dysuria 78.6 (69.5–86.1) 75.0 (57.8–87.9) 80.6 (87.5–99.1) 0.51
Frequent urination 83.5 (74.9–90.1) 83.3 (67.2–93.6) 83.6 (72.5–91.5) 0.97
Decreased urine output 37.9 (28.5–48.0) 47.2 (30.4–64.5) 32.8 (21.8–45.4) 0.15
Nausea/vomiting 20.4 (13.1–29.5) 36.1 (20.8–53.8) 11.9 (5.3–22.2) <0.01
Vaginal discharge 13.6 (7.6–21.8) 11.1 (3.1–26.1) 14.9 (7.4–25.7) 0.59
Abdominal pain 54.4 (44.3–64.2) 75.0 (57.8–87.9) 43.3 (31.2–56.0) <0.01
Back pain 42.7 (33.0–52.8) 69.4 (51.9–83.7) 28.4 (18.0–40.7) <0.01
Onset of symptoms
< 4 days 60.8 (50.6–70.3) 41.7 (25.5–59.2) 71.2 (58.7–81.7) 0.01
4–7 days 29.4 (20.8–39.3) 41.7 (25.5–59.2) 22.7 (13.3–34.7)
> 7 days 9.8 (4.8–17.3) 16.7 (6.4–32.8) 6.1 (1.7–14.8)
P-Values that appear in bold are significant at p < 0.05
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Reasons for this might include the perception that FQ
are more effective, or the shorter treatment duration of
FQ, which providers may perceive as more convenient
for patients. Furthermore, 22.2 % of patients with symp-
toms of pyelonephritis received this medication, despite
recommendations not to use nitrofurantoin for patients
with pyelonephritis. Other studies have documented in-
appropriate antibiotic use for common infections in the
ED and other settings [2, 3]. It is also possible that our
structured interview detected symptoms consistent with
pyelonephritis whereas the clinician was basing their as-
sessment on different criteria, including physical exam-
ination. It is nonetheless concerning that there is a
potential for misdiagnosis of these cases.
While UTIs are a common diagnosis and account for
more than 2 million patient visits per year in hospital
based settings alone, overall adherence to treatment
guidelines has been historically low. In a 2011 cross-
sectional study of lower UTIs in a general practice clinic
(n = 658) performed over a 3-month period, researchers
found that antibiotic treatment was given in 634
(96.4 %) cases and only 92 (17.7 %) of these received first
line antibiotics [17].
Although definitive diagnosis of cystitis is made with
clinical symptoms and bacteriuria, dysuria, frequency,
and urgency have all been associated with the diagnosis
of UTI [17, 18]. While the urine dipstick may be helpful
in diagnosing UTI, it is unable to effectively rule it out
with moderate clinical suspicion. Positive leukocyte es-
terase or nitrate has been found to have a positive
likelihood ratio of 2.5 for the diagnosis of UTI [19]. We
found that a negative urinalysis increased the odds of
non-adherence by more than 2-fold, although this was
not statistically significant. This may be because patients
with atypical features or negative results were treated
with antibiotics for other conditions, or because clini-
cians were more likely to use broad spectrum antibiotics,
such as FQ, for an uncertain diagnosis.
There were several limitations to our study. First, we
enrolled participants at a single urban academic center
using a convenience sample, which may not be represen-
tative of other sites. Given the small number of physi-
cians sampled, individual errors or differing practice
styles can influence the study greatly. Nonetheless, we
found similar proportions of FQ use compared to other
studies in and outside the ED setting [15, 20]. Further-
more, while proportions of antibiotic prescribing could
potentially vary between academic and community based
centers, we found no significant prescribing differences
between attending physicians and residents. In addition,
we did not directly ascertain providers’ reasoning re-
garding antibiotic selection, which may have yielded
additional insight into empiric antibiotic selection, such
as coverage for other suspected etiologies. While we
used a clinical diagnosis rather than microbiologic cul-
ture to confirm the diagnosis of UTI, we think our strat-
egy of reviewing charts for inclusion of patients with
uncomplicated cystitis and pyelonephritis based on clin-
ical signs and symptoms as well as change prescribing
practices documented diagnosis is appropriate given
Table 2 Clinical treatment, test results, and adherence to IDSA guidelines for 103 adults with uncomplicated UTI
Characteristics Overall (n = 103) Pyelonephritis (n = 36) Cystitis (n = 67) P-value
% (95 % CI) % (95 % CI) % (95 % CI)
Provider
Attending or PA 65.0 (55–74.2) 47.2 (30.4–64.5) 74.6 (62.5–84.5) 0.01
Resident 35.0 (25.8–45) 52.8 (35.5–69.6) 25.4 (15.5–37.5)
Antibiotics prescribed
Ciprofloxacin 59.2 (49.1–68.8) 47.2 (30.4–64.5) 65.7 (53.1–76.8) 0.09
Nitrofurantoin 20.4 (13.1–29.5) 22.2 (10.1–39.2) 19.4 (10.8–30.9)
TMP-SMX 18.4 (11.5–27.3) 25.0 (12.1–42.2) 14.9 (7.4–25.7)
Other 1.9 (0.2–6.8) 5.6 0.7–18.7) 0.0 (0.0–5.4)
Urinalysis results
Positive 76.7 (67.3–84.5) 72.2 (54.8–85.8) 79.1 (67.4–88.1) 0.43
Negative 23.3 (15.5–32.7) 27.8 (14.2–45.2) 20.9 (11.9–32.6)
Culture results a
Escherichia coli 60.6 (42.1–77.1) 50.0 (24.7–75.3) 70.6 (44–89.7) 0.23
Other pathogen 39.4 (22.9–57.9) 50.0 (24.7–75.3) 29.4 (10.3–56)
Non-adherence to guidelines 63.1 (53.0–72.4) 63.9 (46.2–79.2) 62.7 (50–74.2) 0.90
a Only includes cultures that had pathogen growth (n = 42)
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recommendations for empiric treatment without culture
in most cases with uncomplicated infection [9]. The in-
clusion of pyelonephritis secondary to untreated cystitis
or resistant pathogen was minimized by not enrolling
women who were treated for urinary complaints within
1 month of presentation. However, we cannot eliminate
it as a possibility and thus it represents an important
limitation to our study. We also recognize the small
Table 3 Univariate logistic regression of non-adherence to antibiotic guidelines for uncomplicated UTI
Variable Non-Adherent % OR 95 % CI P-value
Race
Black, non-Hispanic 66.0 1
White, non-Hispanic 59.4 0.8 0.3–1.9 0.54
Hispanic or other race 61.1 0.8 0.3–2.4 0.71
Age
18–29 63.6 1
30–39 61.5 0.9 0.4–2.3 0.85
40+ 63.6 1.0 0.3–3.8 1.00
Clinical history
Sexually active 62.8 0.9 0.3–2.7 0.88
No recent history of UTI 75.0 2.4 1.0–5.7 0.05
Onset of symptoms
< 4 days 67.7 1
4–7 days 56.7 0.6 0.3–1.5 0.30
> 7 days 60.0 0.7 0.2–2.8 0.63
Provider
Attending or PA 64.2 1
Resident 61.1 0.9 0.4–2.0 0.76
Clinical symptoms
Dysuria 64.2 1.2 0.5–3.3 0.66
Frequent urination 61.6 0.7 0.2–2.1 0.49
Decreased urination 61.5 0.9 0.4–2.0 0.80
Nausea/vomiting 42.9 0.3 0.1–0.9 0.04
Vaginal discharge 85.7 4.1 0.9–19.3 0.08
Back pain 61.4 0.9 0.4–2.0 0.75
Abdominal pain 62.5 0.9 0.4–2.1 0.90
Type of UTI
Pyelonephritis 62.8 1
Cystitis 55.6 0.9 0.4–2.2 0.90
Type of UTI with clinical symptom combinations
Cystitis, no other non-urinary symptoms 52.0 1
Cystitis, with back or adnominal pain symptoms only 90.5 8.8 1.7–45.9 0.01
Cystitis, with vaginal discharge 90.0 8.3 0.9–75.7 0.06
Cystitis, with other combinations of non-urinary symptoms 9.1 0.1 0.0–0.8 0.03
Pyelonephritis (any fever or flank pain present) 63.9 1.6 0.6–4.6 0.36
Urinalysis results
Positive 58.2 1
Negative 79.2 2.7 0.9–8.0 0.07
P-Values that appear in bold are significant at p < 0.05
Non-urinary symptoms include: back pain, abdominal pain, fever, flank pain, vaginal discharge, or nausea/vomiting
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sample size may have limited our ability to identify sig-
nificant predictors of non-adherence. Odds ratios for
clinical symptoms have wide confidence intervals and
should be interpreted with caution. While we assumed
adherence with TMP-SMX, microbiologic results show
that > 20 % of isolates from patients with uncomplicated
UTI are resistant to TMP-SMX, however this was not
known to the treating providers during the study enroll-
ment period. Finally, we cannot know whether providers
made antibiotic treatment decisions based on prior mi-
crobiologic culture.
There were several cases where the clinician diagnosis
differed from our case definition. For example, in seven
cases the clinician diagnosis was cystitis in patients with
documented fever or flank pain and in four cases the
clinician diagnosis was pyelonephritis without docu-
mented fever or flank pain. While it is possible that
clinicians based their diagnosis of cystitis versus py-
elonephritis based on physical examination findings,
this calls to question whether patients with symptoms
consistent with pyelonephritis such as flank pain and
fever, may be undertreated, and warrants further
investigation.
Finally, we did not distribute guidelines surrounding
UTI to our clinicians, but we cannot be certain that
awareness of the study did not change prescribing
practices to be more adherent to the recommended
guidelines.
The ED is a unique care setting where physicians must
make quick treatment decisions about prescribing anti-
biotics for UTIs with often incomplete information and
limited opportunity for follow up. A previous study con-
ducted by our group showed that clinical decision mak-
ing regarding antibiotics for patients is complex and is
affected by limited environmental resources, lack of ac-
cess to decision making tools including locally relevant
guidelines, clinical inertia, and perceptions that broad
spectrum antibiotics are superior in cases where follow
up is not feasible [17]. In the case of uncomplicated
UTI, however, this overuse of broad-spectrum antibi-
otics is in fact counterproductive, given the increasing
resistance rates to FQ.
A primary cause of provider non-adherence is a
lack of knowledge of antimicrobial guidelines. A 2000
cross-disciplinary survey of 92 delegates with an inter-
est in UTIs showed that <3 % answered correctly
[21]. While guidelines can be useful to guiding pre-
scribing [22], many ED providers are skeptical as they
feel the ED is a special population and that guidelines
should be locally tailored. Lack of knowledge sur-
rounding guidelines is also common [21]. Strategies
to implement ED interventions in the form of vali-
dated clinical decision rules have yielded mixed re-
sults [23, 24]. However, there are unique facilitators
to successful practice change in the ED, including
interest in novel tools and acceptance of new respon-
sibilities [26]. Interventions to address barriers to
change in the ED include educational outreach, for-
mal feedback to the clinical care team, and process
change [25]. Best practices solutions utilize a multifa-
ceted approach [27, 28]. Novel strategies include embed-
ding guidelines in the electronic health record [29]. A
recent study found that a stewardship intervention that
included an electronic order set with audit and feedback
found that adherence to UTI guidelines increased from
44 % at baseline to 82 % while use of FQ for uncompli-
cated cystitis decreased from 44 to 13 % overall [30].
Given the frequency of visits for uncomplicated UTI in
the ED, and the importance of FQ in contributing to in-
creasing trends in resistance, efforts should focus specific-
ally on the use of FQ in the ED for patients with
uncomplicated infections. However, it remains uncertain
if these effects can be sustained over time and further
studies are urgently needed to help reduce inappropriate
broad-spectrum antibiotic use and improve adherence to
clinical practice guidelines in patients with uncomplicated
UTI and other infections.
Conclusions
63.1 % of patients who were treated in the ED for un-
complicated UTI received antibiotics that did not adhere
to ICPG. The most common characterization of non-
adherence was use of FQ in cystitis, followed by an
inappropriate duration, no initial IV antibiotic for pyelo-
nephritis, and another inappropriate antibiotic choice.
Interestingly, physicians were less likely to be guideline
non-adherent when patient’s reported back or abdominal
pain.
Table 4 Multivariable logistic regression analysis of non-
adherence to antibiotic guidelines for uncomplicated UTI
Variable OR 95 % CI P-value
Clinical history
No recent history of UTI 3.8 1.3–11.4 0.02
Clinical symptoms
Nausea/vomiting 0.4 0.1–1.4 0.14
Type of UTI, symptoms
Cystitis, no other non-urinary symptoms 1
Cystitis, with back or adnominal pain
symptoms only
11.4 2.1–63.0 0.01
Cystitis, with vaginal discharge 12.1 1.1–137.5 0.05
Cystitis, with other combinations of
non-urinary symptoms
0.1 0.0–1.1 0.06
Pyelonephritis (fever or flank pain present) 2.7 0.8–9.3 0.12
P-Values that appear in bold are significant at p < 0.05
Non-urinary symptoms include: back pain, abdominal pain, fever, flank pain,
vaginal discharge, or nausea/vomiting
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